Abiomed Inc (ABMD)
291.12
-3.94 (-1.34%)
USD |
NASDAQ |
Aug 16, 16:00
291.24
+0.12 (+0.04%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 13.24B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -8.27% |
| Valuation | |
| PE Ratio | 61.44 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 12.66 |
| Price to Book Value | 8.619 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 70.98% |
News
Headline
Wire
Time (ET)
Yahoo
08/16 12:08
Yahoo
08/16 08:02
MT Newswires
08/04 09:20
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 10/28/2022* | -- | Results | Q2 2023 | -- | 0.99 | -- | |
| 10/28/2022* | 08:00 EST | Earnings Call | Q2 2023 | -- | -- | -- | |
| 08/04/2022 | -- | Results | Q1 2023 | 1.25 | 1.06 | 17.97% | |
| 08/04/2022 | 08:00 EST | Earnings Call | Q1 2023 | -- | -- | -- | |
| 04/28/2022 | -- | Results | Q4 2022 | 1.16 | 1.05 | 10.12% | |
| 04/28/2022 | 08:00 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 02/03/2022 | -- | Results | Q3 2022 | 1.13 | 0.97 | 16.30% | |
| 02/03/2022 | 08:00 EST | Earnings Call | Q3 2022 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| Abiomed Inc provides temporary mechanical circulatory support devices that are primarily used by interventional cardiologists and heart surgeons. The firm's products are used for patients in need of hemodynamic support before, during, or after angioplasty and heart surgery procedures. Abiomed receives the majority of revenue from its Impella product portfolio, which includes percutaneous micro heart pumps with integration motors and sensors and percutaneous catheter-based axial flow pumps. Abiomed generates the majority of its revenue in the United States. |
| URL | https://www.abiomed.com |
| Investor Relations URL | https://investors.abiomed.com/ |
| HQ State/Province | Massachusetts |
| Sector | Healthcare |
| Industry | Medical Devices |
| Equity Style | Mid Cap/Growth |
| Next Earnings Release | Oct. 28, 2022 (est.) |
| Last Earnings Release | Aug. 04, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of August 15, 2022.
Fundamentals
| Revenue (TTM) | 1.056B |
| Total Expenses (TTM) | 799.77M |
| Net Income (TTM) | 217.58M |
| Total Assets (Quarterly) | 1.704B |
| Total Liabilities (Quarterly) | 167.44M |
| Shareholders Equity (Quarterly) | 1.536B |
| Cash from Operations (TTM) | 298.13M |
| Cash from Investing (TTM) | -263.82M |
| Cash from Financing (TTM) | -18.67M |
Ratings
Profile
Edit
| Abiomed Inc provides temporary mechanical circulatory support devices that are primarily used by interventional cardiologists and heart surgeons. The firm's products are used for patients in need of hemodynamic support before, during, or after angioplasty and heart surgery procedures. Abiomed receives the majority of revenue from its Impella product portfolio, which includes percutaneous micro heart pumps with integration motors and sensors and percutaneous catheter-based axial flow pumps. Abiomed generates the majority of its revenue in the United States. |
| URL | https://www.abiomed.com |
| Investor Relations URL | https://investors.abiomed.com/ |
| HQ State/Province | Massachusetts |
| Sector | Healthcare |
| Industry | Medical Devices |
| Equity Style | Mid Cap/Growth |
| Next Earnings Release | Oct. 28, 2022 (est.) |
| Last Earnings Release | Aug. 04, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| BCSIX | 167.41M USD | 4.26% |
| POAGX | 189.00M USD | 2.64% |
| POGRX | 167.04M USD | 2.36% |
| KONG | 537304.0 USD | 2.16% |
| DBMCX | 49.95M USD | 1.87% |
| RYH | 16.11M USD | 1.68% |
| WMGRX | 91.73M USD | 1.67% |
| HTEC | 1.961M USD | 1.54% |
| XHE | 6.224M USD | 1.34% |
| BMEZ | 32.67M USD | 1.29% |
| IHI | 81.85M USD | 1.17% |
| VWUSX | 300.75M USD | 0.93% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Morningstar | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| ABMD Tweets |